Aptuit LLC and Icagen, Inc. have entered strategic alliance to provide drug discovery customers access to ion channel and transporter technologies and services. The companies will offer comprehensive and integrated drug discovery and development services from gene to quality candidates and beyond in the ion channel and transporter area.

Aptuit’s customers will have access to Icagen’s portfolio of assay tools and technologies for ion channel and transporter research, including its collection of ion channel cell lines and XRpro X-ray fluorescence technology platform. Icagen’s customers will have access to Aptuit’s range of integrated drug discovery services, including medicinal chemistry, in vitro DMPK, discovery pharmacology, computational chemistry and best-in-class analytical discovery support. 

“This alliance allows us to offer our customers access to Aptuit’s integrated drug discovery and development capabilities,” said Richie Cunningham, president and chief executive officer of Icagen, Inc. “Icagen’s ultimate goal is to reduce the time and cost of bringing ion channel and transporter drug candidates to market for our clients. Aptuit’s world leading expertise in integrated drug discovery we believe will increase Icagen’s ability to efficiently advance our clients’ drug candidates through pre-clinical development.” 

Jonathan Goldman, M.D., Aptuit’s chief executive officer said, “Customers have noted our unique capabilities in the medicinal chemistry areas and integrated discovery. We are delighted that this alliance with Icagen, and their expertise in ion channel and transporter technologies, has the potential to put both companies in a position to help our customers increase their chances of successful IND filing.”